Center Laboratories Inc’s (晟德大藥廠) China-based unit, TOT Biopharm International Co Ltd (東曜藥業), is to conduct an initial public offering (IPO) in Hong Kong on Friday next week to raise capital for its new drug business, the firm said yesterday.
The unit plans to raise HK$679.5 million (US$86.7 million) by issuing 90 million new shares at HK$7.55 each, Center Laboratories said in the prospectus.
Although Center Laboratories would see its stake in TOT Biopharm decline from 37.2 to 31 percent due to equity dilution after the IPO, it would remain the firm’s biggest shareholder, the company said in a statement.
‘NATURAL CALL’
It is to be the first time a biopharmaceutical firm with investment from a Taiwanese company conducts an IPO in Hong Kong, even though the Taiwan Stock Exchange has eased regulations to allow biotechnology firms, even if they are unprofitable, to become publicly listed companies.
“It is a natural call [to go public in Hong Kong], as TOT Biopharm has mainly concentrated on China’s oncology market since its establishment in 2009. Being listed on the Hong Kong Stock Exchange will make the firm known to more investors,” Center Laboratories spokeswoman Catherine Lin (林秀月) said by telephone.
The unit, registered in Hong Kong and headquartered in China’s Suzhou Industrial Park, focuses on the research and development, manufacturing and marketing of high-end anti-tumor drugs.
“It is also [Center Laboratories] chairman Lin Rong-jin’s (林榮錦) philosophy that new drug companies should gain financial support worldwide, as it takes a lot of money to develop the drugs,” Lin said.
TOT Biopharm’s other shareholders include the US investment firm Vivo Capital LLC with a 19.02 percent stake and venture capital firm Chengwei Capital (成為資本) with an 11.8 percent stake, she said.
BUSINESS POTENTIAL
Even though the unit has not turned a profit — with cumulative losses last year totaling 7.53 million yuan (US$1.07 million at the current exchange rate), a 55.3 percent increase from 4.85 million yuan in 2017 — it has passed the listing review due to its business potential, Lin said.
TOT Biopharm said that it expects to complete phase III trials in China for TAB008, a biosimilar of Roche Holding AG’s Avastin for the treatment of colorectal cancer, by the end of this year and plans to file a new drug application in March next year.
It added that it has another 11 drugs in the research stage.
Shares of Center Laboratories, which manufactures and markets oral liquid formulations and children’s formulations, gained 9.98 percent to NT$66.1 in Taipei trading yesterday.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts